Therapy Areas: Diabetes
Ocular Therapeutix secures FDA special protocol assessment for AXPAXLI NPDR trial
12 August 2025 -

Biopharmaceutical company Ocular Therapeutix, Inc. (NASDAQ: OCUL) on Tuesday announced it has received a written agreement from t...

MetaVia collaborates with Syntekabio to explore AI-driven indications for DA-1241
5 August 2025 - MetaVia Inc (Nasdaq: MTVA), a US-based clinical-stage biotechnology company focused on transforming cardiometabolic diseases, announced on Monday a research collaboration with Syntekab...
Ascletis completes participant dosing in US obesity clinical study
15 July 2025 - Chinese pharmaceutical company Ascletis Pharma Inc (HKEX: 1672) announced on Monday that that all 28 participants have been dosed in the randomised, double-blind, placebo-controlled stu...
BioLab Holdings' amnion grafts enter multicentre clinical trial
4 July 2025 - BioLab Holdings Inc, a US-based medical manufacturer specialising in wound healing and regenerative therapies, announce on Thursday the launch of a multicentre hybrid platform trial eval...
Apotex's Aflivu Eylea biosimilar receives Health Canada approval in pre-filled syringe and vial formats
3 July 2025 - Apotex Inc., a Canada-based global health company, announced on Wednesday that Health Canada has approved Aflivu (aflibercept), a biosimilar to Eylea, indicated for the treatment of neov...
Predictmedix AI launches mobile diabetes screening platform in India
2 July 2025 - Predictmedix AI Inc (CSE:PMED) (OTC:PMEDF) (FRA:3QP), a developer of artificial intelligence-driven health screening solutions, on Wednesday announced the launch of a mobile, AI-powered ...